Buffett's favorite growth name is on sale and it's probably a good buy

In partnership with

Novaxidil Triple Action Hair Regrowth Treatment

Novaxidil is a Premium OTC Triple Action hair loss treatment that stimulates hair regrowth, prevents further loss, AND nourishes your scalp with a combination of clinically proven ingredients: 5% Minoxidil, 2% K-Conazole, 1% Nicotinamide, Vitamin K, Biotin, and Collagen Peptides.

Our team of MD/PhD's formulated Novaxidil to maximize results while minimizing side effects.

MINOXIDIL 5%: Minoxidil is the Gold Standard for hair regrowth. It achieves this by shortening the telogen phase, extending the anagen phase, increasing blood flow to the scalp, and increasing dermal papilla cell activity.

K-CONAZOLE™ 2%: Studies have shown that K-Conazole™, a proprietary version of the popular compound, blocks the production of dihydrotestosterone (DHT), a hormone linked to male pattern baldness, as effectively as prescription alternatives like FINA without the side effects. It works by inhibiting the 5-alpha reductase (5AR) enzyme, which converts testosterone into DHT.

NICOTINAMIDE 1%: Nicotinamide, also known as niacinamide, has potent effects on hair regrowth. In studies, it has been shown to increase blood flow, and reduce inflammation to the scalp, as well as prevent premature catagen entry, and increase hair thickness. Nicotinamide works in synergy with Minoxidil, and K-Conazole™ to maximize hair regrowth, and minimize loss like no other product on the market!

Before you give up, and start rocking the "bald look," give Novaxidil a try. We're confident you won't regret it.

Learn More

Warren Buffett and Berkshire ($BRK) are not known for their tech bets, with the exception of Apple, of course. The richest investor in the world has skipped all tech stocks… until recently.

Without losing its industrial focus, Berkshire has recently made selective investments in high-growth tech stocks including Snowflake ($SNOW) and Latin American digital bank NuBank ($NU). While the behemoth has exited its position in Snowflake, it still holds a 1.8% stake in the fintech giant, at an average price of $10.

NU shares surged as much as 90% this year before falling 25% in the last 30 days, for no apparent reason. This unjustified selloff has created an attractive entry point in one of the most promising fintech companies in the world. Here’s why:

Subscribe to Premium Membership to read the rest.